+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Aryl Hydrocarbon Receptor - Pipeline Review, H2 2019

  • ID: 4900155
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 110 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Actavalon Inc
  • Ampio Pharmaceuticals Inc
  • Bayer AG
  • Hutchison MediPharma Ltd
  • Magenta Therapeutics Inc
  • Pfizer Inc
  • MORE
Aryl Hydrocarbon Receptor - Pipeline Review, H2 2019

Summary

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target constitutes close to 26 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Aryl Hydrocarbon Receptor - Pipeline Review, H2 2019, outlays comprehensive information on the Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Aryl hydrocarbon receptor is a protein encoded by the AHR gene. It mediates biochemical and toxic effects of halogenated aromatic hydrocarbons. It involved in cell-cycle regulation. It plays an important role in the development and maturation of many tissues. It regulates the circadian clock by inhibiting the basal and circadian expression of the core circadian component PER1. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 1, 1, 12 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Gastrointestinal, Metabolic Disorders and Genetic Disorders which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Atopic Dermatitis (Atopic Eczema), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Multiple Sclerosis, Psoriasis, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Type 1 Diabetes (Juvenile Diabetes), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), Alopecia, Androgen-Sensitive Prostate Cancer, Breast Cancer, Burkitt Lymphoma, Celiac Disease, Globoid Cell Leukodystrophy (Krabbe Disease), Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hematopoietic Stem Cell Transplantation, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Huntington Disease, Inflammatory Bowel Disease, Mantle Cell Lymphoma, Melanoma, Metachromatic Leukodystrophy (MLD), Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), Multiple Myeloma (Kahler Disease), Myasthenia Gravis, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Oral Cancer, Osteoarthritis Pain, Pancreatic Ductal Adenocarcinoma, Pemphigus, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, T-Cell Lymphomas, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Vitiligo.

Furthermore, this report also reviews key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)
  • The report reviews Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Actavalon Inc
  • Ampio Pharmaceuticals Inc
  • Bayer AG
  • Hutchison MediPharma Ltd
  • Magenta Therapeutics Inc
  • Pfizer Inc
  • MORE
Introduction
Report Coverage
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Overview
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Companies Involved in Therapeutics Development
Actavalon Inc
Active Biotech AB
Ampio Pharmaceuticals Inc
AnTolRx Inc
Bayer AG
Dermavant Sciences Inc
Hercules Pharmaceuticals BV
Hutchison MediPharma Ltd
Ikena Oncology Inc
JAGUAHR Therapeutics Pte Ltd
Magenta Therapeutics Inc
Nippon Kayaku Co Ltd
Pfizer Inc
Phenex Pharmaceuticals AG
Shenogen Pharma Group Ltd
Welichem Biotech Inc
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Drug Profiles
Ampion - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-218 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-2416964 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Agonize Aryl Hydrocarbon Receptor for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Agonize Aryl Hydrocarbon Receptor for Multiple Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Agonize Aryl Hydrocarbon Receptor for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cinnabarinic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize Aryl Hydrocarbon Receptor for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize Aryl Hydrocarbon Receptor for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize Aryl Hydrocarbon Receptor for Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Agonize Aryl Hydrocarbon Receptor for Alopecia, Vitiligo and Pemphigus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Agonize Aryl Hydrocarbon Receptor for Psoriasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Antagonize AHR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HP-163 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IK-175 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Dormant Products
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Discontinued Products
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Product Development Milestones
Featured News & Press Releases
Appendix

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Actavalon Inc, H2 2019
Pipeline by Active Biotech AB, H2 2019
Pipeline by Ampio Pharmaceuticals Inc, H2 2019
Pipeline by AnTolRx Inc, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Dermavant Sciences Inc, H2 2019
Pipeline by Hercules Pharmaceuticals BV, H2 2019
Pipeline by Hutchison MediPharma Ltd, H2 2019
Pipeline by Ikena Oncology Inc, H2 2019
Pipeline by JAGUAHR Therapeutics Pte Ltd, H2 2019
Pipeline by Magenta Therapeutics Inc, H2 2019
Pipeline by Nippon Kayaku Co Ltd, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Phenex Pharmaceuticals AG, H2 2019
Pipeline by Shenogen Pharma Group Ltd, H2 2019
Pipeline by Welichem Biotech Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Actavalon Inc
  • Active Biotech AB
  • Ampio Pharmaceuticals Inc
  • AnTolRx Inc
  • Bayer AG
  • Dermavant Sciences Inc
  • Hercules Pharmaceuticals BV
  • Hutchison MediPharma Ltd
  • Ikena Oncology Inc
  • JAGUAHR Therapeutics Pte Ltd
  • Magenta Therapeutics Inc
  • Nippon Kayaku Co Ltd
  • Pfizer Inc
  • Phenex Pharmaceuticals AG
  • Shenogen Pharma Group Ltd
  • Welichem Biotech Inc
Note: Product cover images may vary from those shown
Adroll
adroll